William G Woods

Summary

Affiliation: Children's Healthcare of Atlanta
Country: USA

Publications

  1. ncbi request reprint Screening of infants and mortality due to neuroblastoma
    William G Woods
    AFLAC Cancer Center, Emory University and Children s Healthcare of Atlanta, GA 30322, USA
    N Engl J Med 346:1041-6. 2002
  2. ncbi request reprint Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    J Clin Oncol 20:434-40. 2002
  3. ncbi request reprint Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep
    William G Woods
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta Emory University Department of Pediatrics, Atlanta, Georgia 30322, USA
    Pediatr Blood Cancer 46:565-9. 2006
  4. ncbi request reprint "Let's try it one more, once"
    William G Woods
    Department of Pediatric Hematology Oncology, Hematopoietic Transplantation, Children s Healthcare of Atlanta, Atlanta, Georgia, USA
    Pediatr Blood Cancer 46:271-2. 2006
  5. ncbi request reprint Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
    Steven Neudorf
    American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    Blood 103:3655-61. 2004
  6. ncbi request reprint Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively
    Lubing Gu
    Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 279:52141-9. 2004
  7. pmc Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group
    John T Horan
    Aflac Cancer Center and Blood Disorder Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30332, USA
    J Clin Oncol 26:5797-801. 2008
  8. ncbi request reprint Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53
    Muxiang Zhou
    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Oncogene 22:8137-44. 2003
  9. pmc Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare of Atlanta, Atlanta, Georgia
    Cancer 119:4170-9. 2013
  10. ncbi request reprint Screening for neuroblastoma: the final chapters
    William G Woods
    Children s Healthcare of Atlanta at Emory, Atlanta, GA, USA
    J Pediatr Hematol Oncol 25:3-4. 2003

Detail Information

Publications36

  1. ncbi request reprint Screening of infants and mortality due to neuroblastoma
    William G Woods
    AFLAC Cancer Center, Emory University and Children s Healthcare of Atlanta, GA 30322, USA
    N Engl J Med 346:1041-6. 2002
    ..However, it is unknown whether routine screening for neuroblastoma reduces mortality due to this disease...
  2. ncbi request reprint Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    J Clin Oncol 20:434-40. 2002
    ..We report the first large prospective study of children with myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) treated in a uniform fashion on Children's Cancer Group protocol 2891...
  3. ncbi request reprint Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep
    William G Woods
    Aflac Cancer Center and Blood Disorders Service, Children s Healthcare of Atlanta Emory University Department of Pediatrics, Atlanta, Georgia 30322, USA
    Pediatr Blood Cancer 46:565-9. 2006
    ..This brief review looks at both the advances over the last three decades as well as discusses the challenges moving forward for ultimately curing all children with this disease...
  4. ncbi request reprint "Let's try it one more, once"
    William G Woods
    Department of Pediatric Hematology Oncology, Hematopoietic Transplantation, Children s Healthcare of Atlanta, Atlanta, Georgia, USA
    Pediatr Blood Cancer 46:271-2. 2006
  5. ncbi request reprint Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival
    Steven Neudorf
    American Family Life Assurance Company AFLAC Cancer Center, Emory University Children s Healthcare, Atlanta, GA, USA
    Blood 103:3655-61. 2004
    ..014) were associated with improved relapse-free survival (RFS). Our results show that children older than 10 years are at higher risk for developing severe GVHD; acute GVHD is associated with favorable RFS...
  6. ncbi request reprint Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively
    Lubing Gu
    Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Biol Chem 279:52141-9. 2004
    ..Furthermore, loss of p53-mediated control over ETS-1-dependent transactivation of IKKalpha may represent a novel pathway for the constitutive activation of NF-kB-mediated gene expression and therapy resistance in cancer...
  7. pmc Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group
    John T Horan
    Aflac Cancer Center and Blood Disorder Service, Children s Healthcare of Atlanta, Emory University, Atlanta, GA 30332, USA
    J Clin Oncol 26:5797-801. 2008
    ..Others have maintained that transplantation in first remission should be reserved for patients with high-risk disease. We performed this study to determine how disease risk influences the efficacy of BMT...
  8. ncbi request reprint Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53
    Muxiang Zhou
    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA
    Oncogene 22:8137-44. 2003
    ..Our data suggest that IkBm simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis...
  9. pmc Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials
    William G Woods
    AFLAC Cancer Center, Emory University Children s Healthcare of Atlanta, Atlanta, Georgia
    Cancer 119:4170-9. 2013
    ..A retrospective meta-analysis of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) was performed to determine if differences in outcome exist following treatment on pediatric versus adult oncology treatment regimens...
  10. ncbi request reprint Screening for neuroblastoma: the final chapters
    William G Woods
    Children s Healthcare of Atlanta at Emory, Atlanta, GA, USA
    J Pediatr Hematol Oncol 25:3-4. 2003
  11. ncbi request reprint PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells
    Muxiang Zhou
    Division of Pediatric Hematology Oncology Bone Marrow Transplantation, Emory University School of Medicine, 2040 Ridgewood Drive N E, Atlanta, GA 30322, USA
    Cancer Res 63:6357-62. 2003
    ..Furthermore, loss of PTEN can result in resistance to apoptosis by activating MDM2-mediated antiapoptotic mechanism...
  12. doi request reprint Intracavitary cisplatin therapy for pediatric malignancies
    Howard M Katzenstein
    AFLAC Cancer Center and Blood Disorders Services, Division of Pediatric Hematology Oncology, Emory University School of Medicine and Children s Healthcare of Atlanta, Atlanta, Georgia, USA
    Pediatr Blood Cancer 55:452-6. 2010
    ..The aim of the study was to determine the toxicity and efficacy of locally instilled intracavitary cisplatin in patients with recurrent tumors in closed body cavities...
  13. ncbi request reprint The American Society of Pediatric Hematology/Oncology Distinguished Career Award goes to William Krivit
    William G Woods
    Division of Pediatric Hematology Oncology Blood and Marrow Transplant, Emory University School of Medicine, Atlanta, Georgia, USA
    J Pediatr Hematol Oncol 25:279-81. 2003
  14. doi request reprint Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group
    Lillian Sung
    Department of Paediatrics and Program in Child Health Evaluative Sciences, Hospital for Sick Children, Toronto, ON, Canada
    J Pediatr Hematol Oncol 34:e30-5. 2012
    ..Intensive timing was associated with more severe infections compared with standard timing induction. Prophylactic strategies are likely more important with intensive induction regimens...
  15. pmc Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group
    Richard Aplenc
    Pediatric Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Blood 108:74-80. 2006
    ..Fewer black children than expected had an available family marrow donor...
  16. ncbi request reprint Treatment complications in children diagnosed with neuroblastoma during a screening program
    Stephane Barrette
    Hopital Ste Justine, Montreal, Quebec, Canada
    J Clin Oncol 24:1542-5. 2006
    ..We assess treatment complications in the patients diagnosed during this screening program...
  17. ncbi request reprint Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: report from the Children's Oncology Group
    Dorothy R Barnard
    IWK Health Centre, Halifax, Nova Scotia, Canada
    Pediatr Blood Cancer 49:17-22. 2007
    ..Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features...
  18. ncbi request reprint Outcomes in childhood AML in the absence of transplantation in first remission--Children's Cancer Group (CCG) studies 2891 and CCG 213
    Sharon M Castellino
    ETSU Quillen College of Medicine, Johnson City, Tennessee, USA
    Pediatr Blood Cancer 50:9-16. 2008
    ..The majority of childhood acute myeloid leukemia (AML) patients lack a matched-related bone marrow transplant (BMT) donor in first remission...
  19. ncbi request reprint Incidence of neuroblastoma after a screening program
    Stephane Barrette
    Hopital Ste Justine, Montréal Centre Hospitalier de l Université Laval, Ste Foy, Quebec, Canada
    J Clin Oncol 25:4929-32. 2007
    ..We examined the postscreening incidence of neuroblastoma in the subsequent 5-year birth cohort (May 1994 to April 1999), with follow-up to 2002, to determine whether the incidence remained increased...
  20. ncbi request reprint Screening for neuroblastoma: a resurrected idea?
    John M Maris
    Center for Childhood Cancer Research, Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA 19104, USA
    Lancet 371:1142-3. 2008
  21. ncbi request reprint Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group
    Todd A Alonzo
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Pediatr Hematol Oncol 24:627-35. 2002
    ....
  22. ncbi request reprint Acute myeloid leukemia and myelodysplastic syndrome in children treated for cancer: comparison with primary presentation
    Dorothy R Barnard
    Dalhousie University, Halifax, NS
    Blood 100:427-34. 2002
    ..The findings of this study confirm that most children with tMDS/tAML have disease resistant to current therapies. Standard-timing induction appears less effective for this population...
  23. ncbi request reprint Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia
    Eric L Sievers
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA the Department of Pediatrics, University of Washington, Seattle, WA 98109, USA
    Blood 101:3398-406. 2003
    ..Among patients in whom a marrow sample was available for analysis at the end of consolidation therapy, overall survival at 3 years was 41% versus 69% for patients with and without occult leukemia, respectively (P =.0058)...
  24. ncbi request reprint Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia
    Soheil Meshinchi
    Fred Hutchinson Cancer Research Center, Division of Clinical Research, D4 100, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:1474-9. 2003
    ..38). Activating mutations in the RTK/ras signaling pathway are common in pediatric AML, and their presence may identify a population at higher risk of poor outcome who may benefit from allogeneic BM transplantation...
  25. ncbi request reprint Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891
    Alan S Gamis
    Section of Hematology Oncology Blood and Marrow Transplantation, Children s Mercy Hospital and Clinics, 2401 Gillham Rd, Kansas City, MO 64108, USA
    J Clin Oncol 21:3415-22. 2003
    ..To determine the outcome of children with Down syndrome (DS) and acute myeloid leukemia (AML) receiving standard timing chemotherapy without bone marrow transplantation (BMT), with determination of prognostic factors...
  26. ncbi request reprint Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia
    Donna L Johnston
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 123:431-5. 2003
    ..However, five of six evaluable patients with colonies negative for monosomy 7 entered remission. These data support the hypothesis that leukaemic involvement of early progenitor cells affects the response to induction chemotherapy...
  27. ncbi request reprint All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
    Martin S Tallman
    Northwestern University, Feinburg School of Medicine, Department of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Blood 100:4298-302. 2002
    ..The improvement in outcome with ATRA in APL was maintained with long-term follow-up...
  28. ncbi request reprint Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia
    William Tse
    Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, USA
    Blood 104:3058-63. 2004
    ..01). AF1q expression may correlate with clinical outcome in pediatric AML, although it is not clear if AF1q is simply a marker of a more primitive phenotype or contributes directly to leukemogenesis...
  29. ncbi request reprint Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an American view
    Allen R Chen
    Department of Oncology, Division of Pediatric Oncology, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Baltimore, MD 21287, USA
    Br J Haematol 118:378-84. 2002
  30. ncbi request reprint Health and economic benefits of well-designed evaluations: some lessons from evaluating neuroblastoma screening
    Lee Soderstrom
    Department of Economics, McGill University, 855 Sherbrooke W, Montreal, Quebec, H3A 2T7, Canada
    J Natl Cancer Inst 97:1118-24. 2005
    ..It screened most Quebec newborns between 1989 and 1994 for neuroblastoma. As previously reported, the screening did not reduce neuroblastoma mortality and caused adverse health effects...
  31. pmc Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961
    Draga Barbaric
    Division of Hematology Oncology BMT, BC s Children s Hospital, Vancouver, BC, Canada
    Blood 109:2314-21. 2007
    ..There was no significant outcome difference between DS-associated AML-M0 and non-M0 children. This study suggests that intensively treated non-DS-associated AML-M0 children have an inferior outcome compared with children with non-M0 AML...
  32. ncbi request reprint Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
    Henrik Hasle
    Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark
    Blood 109:4641-7. 2007
    ..Childhood AML with chromosome 7 aberrations represents a heterogeneous group of disorders with additional cytogenetic aberrations having a major prognostic impact which should be reflected in future risk-group stratification...
  33. ncbi request reprint Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group
    Kathryn E Dusenbery
    University of Minnesota, Minneapolis, USA
    J Pediatr Hematol Oncol 25:760-8. 2003
    ..To describe features of patients with acute myeloid leukemia presenting with extramedullary leukemic tumors (EML)...
  34. pmc Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group
    Joanne M Hilden
    The Children s Hospital at the Cleveland Clinic, OH 44195, USA
    Blood 108:441-51. 2006
    ..MLL/11q23 rearrangement, CD10 expression, and age are important prognostic factors in infant ALL, but molecular 11q23 translocation partners do not predict outcome...
  35. ncbi request reprint Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia
    Donna L Johnston
    Division of Hematology Oncology, Children s Hospital of Eastern Ontario, Ottawa, Ontario, Canada
    J Clin Oncol 23:9172-8. 2005
    ..CNS relapse of pediatric acute myeloid leukemia (AML) is an infrequent occurrence. This review examines the risk factors and therapy used for patients with an isolated CNS relapse...
  36. ncbi request reprint Substitute "prostate cancer" for "neuroblastoma"?
    William G Woods
    J Clin Oncol 20:1154-5. 2002